StockMacro
Menu

Roivant Sciences

$38.66 +30% in 6 monthsMarket cap $28.0B

ROIV on XNAS, Health Care, Roivant Sciences Ltd., job postings

Measures activity, not value. Not investment advice.

Revenue rose 22 times to $35.1M as insiders sold $111.5M in 90 days.

  • BadNet loss $344.4M over 12 months, free cash flow minus $33.3M
  • BadShort interest 6.3% of shares, up 13% on the prior report

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Industry
Pharmaceutical preparations (Health Care)
Employees
721
Website
roivant.com
Listed
Nasdaq, US
Last results
9 Nov 2026
Next results
expected around 5 Feb 2027 (an estimate: a year ago it reported on 6 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $35.1M, net loss $191.6M.
Quarter to 31 Dec 2021: revenue $24.3M, net income -$284.5MQuarter to 31 Dec 2021: revenue $24.3M, net income -$284.5MQuarter to 31 Mar 2022: revenue $9.2M, net income -$270.1MQuarter to 31 Mar 2022: revenue $9.2M, net income -$270.1MQuarter to 30 Jun 2022: revenue $4.3M, net income -$331.8MQuarter to 30 Jun 2022: revenue $4.3M, net income -$331.8MQuarter to 30 Sep 2022: revenue $12.5M, net income -$291.6MQuarter to 30 Sep 2022: revenue $12.5M, net income -$291.6MQuarter to 31 Dec 2022: revenue $17.1M, net income -$352.0MQuarter to 31 Dec 2022: revenue $17.1M, net income -$352.0MQuarter to 31 Mar 2023: revenue $27.4M, net income -$33.6MQuarter to 31 Mar 2023: revenue $27.4M, net income -$33.6MQuarter to 30 Jun 2023: revenue $21.6M, net income -$291.8MQuarter to 30 Jun 2023: revenue $21.6M, net income -$291.8MQuarter to 30 Sep 2023: revenue $37.1M, net income -$304.3MQuarter to 30 Sep 2023: revenue $37.1M, net income -$304.3MQuarter to 31 Dec 2023: revenue $37.1M, net income $5.1BQuarter to 31 Dec 2023: revenue $37.1M, net income $5.1BQuarter to 31 Mar 2024: revenue $28.9M, net income -$151.1MQuarter to 31 Mar 2024: revenue $28.9M, net income -$151.1MQuarter to 30 Jun 2024: revenue –, net income $95.3MQuarter to 30 Sep 2024: revenue $4.5M, net income -$230.2MQuarter to 30 Sep 2024: revenue $4.5M, net income -$230.2MQuarter to 31 Dec 2024: revenue $9.0M, net income $169.4MQuarter to 31 Dec 2024: revenue $9.0M, net income $169.4MQuarter to 31 Mar 2025: revenue –, net income -$206.5MQuarter to 30 Jun 2025: revenue $2.2M, net income -$223.4MQuarter to 30 Jun 2025: revenue $2.2M, net income -$223.4MQuarter to 30 Sep 2025: revenue $1.6M, net income -$113.5MQuarter to 30 Sep 2025: revenue $1.6M, net income -$113.5MQuarter to 31 Dec 2025: revenue $2.0M, net income -$265.9MQuarter to 31 Dec 2025: revenue $2.0M, net income -$265.9MQuarter to 31 Mar 2026: revenue –, net income $303.0MQuarter to 30 Jun 2026: revenue $1.4M, net income -$189.8MQuarter to 30 Jun 2026: revenue $1.4M, net income -$189.8MQuarter to 30 Sep 2026: revenue $35.1M, net income -$191.6MQuarter to 30 Sep 2026: revenue $35.1M, net income -$191.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $5.1B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$35.1M-$191.6M
30 Jun 2026$1.4M-$189.8M
31 Mar 2026–$303.0M
31 Dec 2025$2.0M-$265.9M
30 Sep 2025$1.6M-$113.5M
30 Jun 2025$2.2M-$223.4M
31 Mar 2025–-$206.5M
31 Dec 2024$9.0M$169.4M
30 Sep 2024$4.5M-$230.2M
30 Jun 2024–$95.3M
31 Mar 2024$28.9M-$151.1M
31 Dec 2023$37.1M$5.1B
30 Sep 2023$37.1M-$304.3M
30 Jun 2023$21.6M-$291.8M
31 Mar 2023$27.4M-$33.6M
31 Dec 2022$17.1M-$352.0M
30 Sep 2022$12.5M-$291.6M
30 Jun 2022$4.3M-$331.8M
31 Mar 2022$9.2M-$270.1M
31 Dec 2021$24.3M-$284.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $41.1M –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$344.4M -$374.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.57 -$0.56
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -838% – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -8.2% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$33.3M -$784.4M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $4.2B $4.4B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$4.2B (net cash) -$4.4B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $5.55
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 682 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 579 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 7.0 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Roivant SciencesROIV (this company) $28.0Bloss682–-838%
Royalty PharmaRPRX $30.5B45.411.6+11%25.7%
InsmedINSM $31.0Bloss20.4+240%-39.9%
ZoetisZTS $32.1B12.93.4+1.0%26.1%
United TherapeuticsUTHR $23.6B19.27.4+1.9%38.6%
ViatrisVTRS $22.5Bloss1.5+4.3%-4.1%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$111.5M

bought $0, sold $111.5M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+5.5%

518 13F filers vs 491

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

80%

578.7M shares held by 13F filers (30 Sep 2026) of 724.6M outstanding (3 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.3%

45.5M shares sold short (30 Oct 2026) of 724.6M outstanding (3 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.1

45.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+13%

40.3M shares sold short in the report before, 45.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

72%

72% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

10

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-97%

$208K vs $7.8M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$60K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

0

0 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

0 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Revenue $35.1M, 22× a year earlier

Price $38.66 on 20 Nov 2026, +91% over 12 months (12-month range $20.10 to $41.85)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $609.9M in the last 12 months (the 12 months before: -$230.1M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, +150% on the 12 months before.
Revenue per quarter. Revenue $35.1M in the latest quarter, +2136% on a year earlier.
Capital spending per quarter. Capital spending $208K in the latest quarter, -97% on a year earlier.
Institutional holders (13F filers). 518 13F filers reported holding it in the latest 13F quarter, +62% on a year earlier.
Lobbying spend. Lobbying spend: $60K published in the last 12 months, -62% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
10 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 35.1M vs usual 3.3M (2026-09-30); 22.4x the same period a year earlier
5 Aug 2026Sharp changeLobbying on a new issue: lobbying on a new issue: CPT (2026-06-30)
11 Nov 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 7.8M vs usual 888K (2025-09-30); 7.9x the same period a year earlier
17 Jul 2025Lobbying filinglobbying engagement terminated (NOVEL STRATEGIES (FKA) PRISM GROUP)
20 Mar 20258-K and other filingsDirector or officer change
21 Feb 20258-K and other filingsDirector or officer change
21 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Oct 20248-K and other filingsA major agreement ended
14 Dec 20238-K and other filingsCompleted an acquisition or asset sale
14 Nov 2023Sharp changeShort interest spike: short interest spike, 33.2M vs usual 14.5M (2023-10-31); 2.7x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 35.5M vs usual 14.3M (2023-10-13); 3.0x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 32.0M vs usual 14.2M (2023-09-29); 2.8x the same period a year earlier
4 Aug 20238-K and other filingsDirector or officer change
4 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jul 2023Lobbying filinglobbying engagement terminated (S-3 GROUP)
18 Jul 2023Sharp changeShort interest spike: short interest spike, 23.0M vs usual 12.3M (2023-06-30); 3.5x the same period a year earlier
23 Jun 2023Lobbying filingnew lobbying registration (NOVEL STRATEGIES (FKA) PRISM GROUP)
31 Mar 2023Lobbying filingnew lobbying registration (S-3 GROUP)
16 Mar 20238-K and other filingsDirector or officer change
21 Feb 20238-K and other filingsDirector or officer change
29 Nov 2022Sharp changeShort interest spike: short interest spike, 12.3M vs usual 2.9M (2022-11-15); 9.3x the same period a year earlier
23 Nov 20228-K and other filingsDirector or officer change
15 Nov 2022Sharp changeShort interest spike: short interest spike, 12.3M vs usual 2.9M (2022-10-31); 9.5x the same period a year earlier
21 Sep 20228-K and other filingsA major agreement ended
21 Sep 20228-K and other filingsDirector or officer change
28 Jun 20228-K and other filingsDirector or officer change
28 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Apr 2022Lobbying filinglobbying engagement terminated (THE CONAFAY GROUP, LLC)
31 Mar 20228-K and other filingsRegistered new securities for sale (S-1)
17 Feb 20228-K and other filingsRegistered new securities for sale (S-1)
22 Dec 20218-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Mar 2022: -$1.6M published
Month from 1 Apr 2022: -$169K published
Month from 1 May 2022: -$1.1M published
Month from 1 Jun 2022: -$164K published
Month from 1 Jul 2022: -$169K published
Month from 1 Aug 2022: -$142K published
Month from 1 Sep 2022: -$123K published
Month from 1 Oct 2022: -$162K published
Month from 1 Nov 2022: -$27.5M published
Month from 1 Dec 2022: -$1.0M published
Month from 1 Jan 2023: -$1.1M published
Month from 1 Feb 2023: -$31.8M published
Month from 1 Mar 2023: -$96.0M published
Month from 1 Apr 2023: -$3.9M published
Month from 1 May 2023: -$6.6M published
Month from 1 Jun 2023: -$262.1M published
Month from 1 Jul 2023: -$5.6M published
Month from 1 Aug 2023: -$3.6M published
Month from 1 Sep 2023: -$10.2M published
Month from 1 Oct 2023: -$254.0M published
Month from 1 Jan 2024: -$33.1M published
Month from 1 Feb 2024: -$1.1M published
Month from 1 Sep 2024: -$84.1M published
Month from 1 Oct 2024: -$1.2M published
Month from 1 Nov 2024: -$1.1M published
Month from 1 Dec 2024: -$16.8M published
Month from 1 Jan 2025: -$5.3M published
Month from 1 Feb 2025: -$8.0M published
Month from 1 Mar 2025: -$8.2M published
Month from 1 Apr 2025: -$1.0M published
Month from 1 May 2025: -$11.2M published
Month from 1 Jun 2025: -$33.8M published
Month from 1 Jul 2025: -$1.2M published
Month from 1 Aug 2025: -$1.2M published
Month from 1 Sep 2025: -$47.9M published
Month from 1 Oct 2025: -$27.3M published
Month from 1 Nov 2025: -$68.3M published
Month from 1 Dec 2025: -$164.8M published
Month from 1 Jan 2026: -$33.3M published
Month from 1 Feb 2026: -$129.0M published
Month from 1 Mar 2026: -$8.8M published
Month from 1 Apr 2026: -$14.8M published
Month from 1 May 2026: -$6.1M published
Month from 1 Jun 2026: -$40.7M published
Month from 1 Jul 2026: -$64.4M published
Month from 1 Aug 2026: -$36.5M published
Month from 1 Sep 2026: -$8.4M published
Month from 1 Oct 2026: -$22.3M published
Month from 1 Nov 2026: -$80.9M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 4 published
Quarter from 1 Apr 2022: 2 published
Quarter from 1 Jul 2022: 4 published
Quarter from 1 Oct 2022: 2 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Jul 2024: 2 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Jul 2026: 5 published
Revenue per quarter
Quarter ended 31 Dec 2020: $5.8M; public on 15 Feb 2022
Quarter ended 31 Dec 2021: $24.3M, +323% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $9.2M; public on 29 Jun 2022
Quarter ended 30 Jun 2022: $4.3M, -44% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $12.5M, -10% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $17.1M, -30% on a year earlier; public on 14 Feb 2023
Quarter ended 31 Mar 2023: $27.4M, +197% on a year earlier; public on 29 Jun 2023
Quarter ended 30 Jun 2023: $21.6M, +401% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $37.1M, +196% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $37.1M, +118% on a year earlier; public on 14 Feb 2024
Quarter ended 31 Mar 2024: $28.9M, +5.7% on a year earlier; public on 31 May 2024
Quarter ended 30 Sep 2024: $4.5M, -88% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $9.0M, -76% on a year earlier; public on 11 Feb 2025
Quarter ended 30 Jun 2025: $2.2M; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $1.6M, -65% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $2.0M, -78% on a year earlier; public on 7 Feb 2026
Quarter ended 30 Jun 2026: $1.4M, -34% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $35.1M, +2136% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $107K; public on 15 Feb 2022
Quarter ended 31 Dec 2021: $6.1M, +5576% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $6.3M; public on 29 Jun 2022
Quarter ended 30 Jun 2022: $7.5M, +219% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $3.1M, +12% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $508K, -92% on a year earlier; public on 14 Feb 2023
Quarter ended 31 Mar 2023: $1.6M, -74% on a year earlier; public on 29 Jun 2023
Quarter ended 30 Jun 2023: $403K, -95% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $275K, -91% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $355K, -30% on a year earlier; public on 14 Feb 2024
Quarter ended 31 Mar 2024: $349K, -78% on a year earlier; public on 31 May 2024
Quarter ended 30 Jun 2024: $965K, +139% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $996K, +262% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $1.8M, +415% on a year earlier; public on 11 Feb 2025
Quarter ended 31 Mar 2025: $811K, +132% on a year earlier; public on 30 May 2025
Quarter ended 30 Jun 2025: $4.0M, +318% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $7.8M, +688% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Mar 2026: $1.3M, +55% on a year earlier; public on 21 May 2026
Quarter ended 30 Jun 2026: $419K, -90% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $208K, -97% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 38; public on 14 Feb 2022
31 Mar 2022 report: 51; public on 16 May 2022
30 Jun 2022 report: 69; public on 15 Aug 2022
30 Sep 2022 report: 70; public on 14 Nov 2022
31 Dec 2022 report: 107; public on 14 Feb 2023
31 Mar 2023 report: 141; public on 15 May 2023
30 Jun 2023 report: 167; public on 14 Aug 2023
30 Sep 2023 report: 193; public on 14 Nov 2023
31 Dec 2023 report: 211; public on 14 Feb 2024
31 Mar 2024 report: 248; public on 15 May 2024
30 Jun 2024 report: 282; public on 14 Aug 2024
30 Sep 2024 report: 276; public on 14 Nov 2024
31 Dec 2024 report: 305; public on 14 Feb 2025
31 Mar 2025 report: 301; public on 15 May 2025
30 Jun 2025 report: 325; public on 14 Aug 2025
30 Sep 2025 report: 319; public on 14 Nov 2025
31 Dec 2025 report: 383; public on 17 Feb 2026
31 Mar 2026 report: 427; public on 15 May 2026
30 Jun 2026 report: 491; public on 14 Aug 2026
30 Sep 2026 report: 518; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $20K published
Quarter from 1 Apr 2023: $20K published
Quarter from 1 Oct 2023: $60K published
Quarter from 1 Jan 2024: $140K published
Quarter from 1 Apr 2024: $60K published
Quarter from 1 Jul 2024: $60K published
Quarter from 1 Oct 2024: $60K published
Quarter from 1 Jan 2025: $60K published
Quarter from 1 Apr 2025: $60K published
Quarter from 1 Jul 2025: $40K published
Quarter from 1 Jul 2026: $30K published
Quarter from 1 Oct 2026: $30K published

What is unusual now

  • Made public in the last 90 days: it reported revenue of $35.1M for the quarter ended 30 Sep 2026, 22× the same quarter last year.
  • Quarterly revenue change: reported revenue of $35.1M for the quarter ended 30 Sep 2026, 22× the same quarter last year Public on 10 Nov 2026.
  • Lobbying on a new issue: lobbying on a new issue Public on 5 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $609.9M in the last 12 months (the 12 months before: -$230.1M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 12 sales, $111.5M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026QVT Financial LPDirector by DeputizationSell1,381,762$38.75$53.5MForm 4
12 Nov 2026Richard PulikCFOSellafter exercising options300,000$41.58$12.5MForm 4
12 Nov 2026Eric VenkerPresident & Immunovant CEOSellplanned in advance (10b5-1)187,943$40.53$7.6MForm 4
5 Nov 2026Eric VenkerPresident & Immunovant CEOSellplanned in advance (10b5-1)200,000$36.31$7.3MForm 4
30 Oct 2026Eric VenkerPresident & Immunovant CEOSellplanned in advance (10b5-1)200,000$36.59$7.3MForm 4
22 Oct 2026Eric VenkerPresident & Immunovant CEOSellplanned in advance (10b5-1)200,000$35.11$7.0MForm 4
5 Oct 2026Epperly Melissa B,DirectorSellplanned in advance (10b5-1); after exercising options17,750$36.10$641KForm 4
2 Oct 2026Eric VenkerPresident & Immunovant CEOSellplanned in advance (10b5-1); after exercising options200,000$36.62$7.3MForm 4

518 institutions reported shares at the end of Q3 2026, 80% of the shares outstanding; 94 opened a position, 68 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)85.6M11.8%$3.1B+4.6M+5.6%
BlackRock, Inc.61.9M8.54%$2.3B+13.6M+28%
Morgan Stanley38.6M5.33%$1.4B-4.0M-9.4%
QVT Financial LP23.7M3.27%$867.6MNo change
Vanguard Capital Management LLC23.1M3.19%$845.8M+1.0M+4.5%
State Street Corp22.4M3.09%$819.2M+4.6M+26%
Farallon Capital Management, L.L.C.21.7M3.00%$795.2M+7.4M+52%
Vanguard Portfolio Management LLC21.7M2.99%$792.0M+16K+0.1%
UBS Group AG13.9M1.92%$509.4M-3.5M-20%
Geode Capital Management, LLC12.5M1.73%$468.0M+847K+7.3%

Company events

All 25 company events

In 12 months: 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
3 Mar 2026Signed a major agreement8-K
20 Mar 2025Director or officer change8-K
21 Feb 2025Director or officer change8-K
28 Oct 2024A major agreement ended8-K
23 Sep 2024Signed a major agreement8-K
30 May 2024Signed a major agreement8-K
14 Dec 2023Completed an acquisition or asset sale8-K
23 Oct 2023Signed a major agreement8-K

10 open postings; careers site tracked since 20 Nov 2026. Most in Data & analytics 30%, Finance & accounting 20%, People & recruiting 10%, Software engineering 10%.

PostedJobLocation
10 Nov 2026Payroll AnalystFinance & accountingRoivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States
9 Nov 2026Stock Plan AdministratorPeople & recruitingRoivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States
28 Sep 2026Accounting Operations AssociateFinance & accountingRoivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States
19 Aug 2026Senior Solution Architect, Finance SystemsSolutions & sales engineeringRoivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States
25 Jun 2026Senior AnalystData & analyticsRoivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States
2 Jun 2026Principal, Data & AnalyticsData & analyticsRoivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States
2 Jun 2026Principal, BiostatisticianData & analyticsRoivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States
1 Dec 2025Founding Engineer, Roivant HealthSoftware engineeringRoivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States

Reported lobbying spend: $30K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 May 2025EndedNovel Strategies (Fka) Prism Groupfor Genevant Sciences, Inc.Healthcare mattersHealth issuesFiling
24 May 2023EndedS-3 Groupfor Genevant Sciences, Inc.Healthcare mattersHealth issuesFiling
5 May 2023NewNovel Strategies (Fka) Prism Groupfor Genevant Sciences, Inc.Healthcare mattersHealth issuesFiling
25 Feb 2023NewS-3 Groupfor Genevant Sciences, Inc.Healthcare mattersHealth issuesFiling
1 Jan 2022EndedThe Conafay Group, LLCfor Roivant Sciences, Inc.Not statedFiling
17 Jun 2021EndedBaker Donelson Bearman Caldwell & Berkowitzfor Roivant Sciences, Inc.Not statedFiling
6 Feb 2021NewBaker Donelson Bearman Caldwell & Berkowitzfor Roivant Sciences, Inc.Issues related to COVID-19 therapy development and approval.Health issuesFiling
31 May 2020EndedTiber Creek Health Strategies, Inc.for Peck Madigan Jones (On Behalf Of Roivant Sciences, Inc.)Development of therapeutics for COVID-19 and other respiratory conditionsPharmacy, Health issuesFiling
Timeline

Timeline

Changes and notable records, by the date each became public

  1. 10 Nov 2026Financials change

    reported revenue of $35.1M for the quarter ended 30 Sep 2026, 22× the same quarter last year.

    Same quarter last year: $1.6M; its normal quarter is $3.3M.

    See the evidence
    This period
    $35.1M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $3.3M
    Typical spread (median absolute deviation)
    $1.8M
    How far from its usual level
    +11.8
    Same quarter last year
    $1.6M
    History used
    2,283 days
    2023-12-31: $37.1M2024-03-31: $28.9M2024-09-30: $4.5M2024-12-31: $9.0M2025-06-30: $2.2M2025-09-30: $1.6M2025-12-31: $2.0M2026-06-30: $1.4M2026-09-30: $35.1M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $3.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 5 Aug 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['CPT']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    10536988
  3. 11 Nov 2025Financials change

    spent $7.8M on capital projects in the quarter ended 30 Sep 2025, 7.9× the same quarter last year.

    Same quarter last year: $996K; its normal quarter is $888K.

    See the evidence
    This period
    $7.8M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $888K
    Typical spread (median absolute deviation)
    $536K
    How far from its usual level
    +7.0
    Same quarter last year
    $996K
    History used
    1,918 days
    2023-09-30: $275K2023-12-31: $355K2024-03-31: $349K2024-06-30: $965K2024-09-30: $996K2024-12-31: $1.8M2025-03-31: $811K2025-06-30: $4.0M2025-09-30: $7.8M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $888K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  4. 19 Sep 2025Insiders record

    Gline Matthew (CEO) bought 3,315 shares of ROIV ($49,957) (dated 18 Sep 2025)

  5. 17 Jul 2025Lobbying record

    GENEVANT SCIENCES, INC.: lobbying engagement terminated (NOVEL STRATEGIES (FKA) PRISM GROUP) (dated 31 May 2025)

  6. 20 Mar 2025Filings record

    Director or officer change

  7. 21 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 21 Feb 2025Filings record

    Director or officer change

  9. 28 Oct 2024Filings record

    A major agreement ended

  10. 14 Dec 2023Filings record

    Completed an acquisition or asset sale

  11. 10 Nov 2023Short interest and volume change

    had 33.2M shares sold short in the 31 Oct 2023 report, 2.7× the same report last year.

    Same report last year: 12.3M; its normal report is 14.5M.

    See the evidence
    This period
    33.2M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    14.5M
    Typical spread (median absolute deviation)
    2.6M
    How far from its usual level
    +4.9
    Same report last year
    12.3M
    History used
    746 days
    2022-10-31: 12.3M2022-11-15: 12.3M2022-11-30: 12.6M2022-12-15: 14.2M2022-12-30: 16.4M2023-01-13: 17.4M2023-01-31: 12.8M2023-02-15: 10.7M2023-02-28: 10.6M2023-03-15: 10.4M2023-03-31: 13.9M2023-04-14: 14.6M2023-04-28: 14.0M2023-05-15: 14.4M2023-05-31: 14.2M2023-06-15: 16.1M2023-06-30: 23.0M2023-07-14: 20.9M2023-07-31: 21.1M2023-08-15: 20.4M2023-08-31: 21.2M2023-09-15: 18.3M2023-09-29: 32.0M2023-10-13: 35.5M2023-10-31: 33.2M
    the 31 Oct 2023 report24 earlier reportsnormal: 14.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 25 Oct 2023Short interest and volume change

    had 35.5M shares sold short in the 13 Oct 2023 report, 3.0× the same report last year.

    Same report last year: 11.7M; its normal report is 14.3M.

    See the evidence
    This period
    35.5M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    14.3M
    Typical spread (median absolute deviation)
    2.4M
    How far from its usual level
    +6.1
    Same report last year
    11.7M
    History used
    728 days
    2022-10-14: 11.7M2022-10-31: 12.3M2022-11-15: 12.3M2022-11-30: 12.6M2022-12-15: 14.2M2022-12-30: 16.4M2023-01-13: 17.4M2023-01-31: 12.8M2023-02-15: 10.7M2023-02-28: 10.6M2023-03-15: 10.4M2023-03-31: 13.9M2023-04-14: 14.6M2023-04-28: 14.0M2023-05-15: 14.4M2023-05-31: 14.2M2023-06-15: 16.1M2023-06-30: 23.0M2023-07-14: 20.9M2023-07-31: 21.1M2023-08-15: 20.4M2023-08-31: 21.2M2023-09-15: 18.3M2023-09-29: 32.0M2023-10-13: 35.5M
    the 13 Oct 2023 report24 earlier reportsnormal: 14.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 12 Oct 2023Short interest and volume change

    had 32.0M shares sold short in the 29 Sep 2023 report, 2.8× the same report last year.

    Same report last year: 11.3M; its normal report is 14.2M.

    See the evidence
    This period
    32.0M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    14.2M
    Typical spread (median absolute deviation)
    2.4M
    How far from its usual level
    +5.1
    Same report last year
    11.3M
    History used
    714 days
    2022-09-30: 11.3M2022-10-14: 11.7M2022-10-31: 12.3M2022-11-15: 12.3M2022-11-30: 12.6M2022-12-15: 14.2M2022-12-30: 16.4M2023-01-13: 17.4M2023-01-31: 12.8M2023-02-15: 10.7M2023-02-28: 10.6M2023-03-15: 10.4M2023-03-31: 13.9M2023-04-14: 14.6M2023-04-28: 14.0M2023-05-15: 14.4M2023-05-31: 14.2M2023-06-15: 16.1M2023-06-30: 23.0M2023-07-14: 20.9M2023-07-31: 21.1M2023-08-15: 20.4M2023-08-31: 21.2M2023-09-15: 18.3M2023-09-29: 32.0M
    the 29 Sep 2023 report24 earlier reportsnormal: 14.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 4 Aug 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 4 Aug 2023Filings record

    Director or officer change

  16. 20 Jul 2023Lobbying record

    GENEVANT SCIENCES, INC.: lobbying engagement terminated (S-3 GROUP) (dated 24 May 2023)

  17. 13 Jul 2023Short interest and volume change

    had 23.0M shares sold short in the 30 Jun 2023 report, 3.5× the same report last year.

    Same report last year: 6.5M; its normal report is 12.3M.

    See the evidence
    This period
    23.0M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    12.3M
    Typical spread (median absolute deviation)
    1.9M
    How far from its usual level
    +3.9
    Same report last year
    6.5M
    History used
    623 days
    2022-06-30: 6.5M2022-07-15: 8.2M2022-07-29: 8.6M2022-08-15: 9.4M2022-08-31: 10.0M2022-09-15: 10.4M2022-09-30: 11.3M2022-10-14: 11.7M2022-10-31: 12.3M2022-11-15: 12.3M2022-11-30: 12.6M2022-12-15: 14.2M2022-12-30: 16.4M2023-01-13: 17.4M2023-01-31: 12.8M2023-02-15: 10.7M2023-02-28: 10.6M2023-03-15: 10.4M2023-03-31: 13.9M2023-04-14: 14.6M2023-04-28: 14.0M2023-05-15: 14.4M2023-05-31: 14.2M2023-06-15: 16.1M2023-06-30: 23.0M
    the 30 Jun 2023 report24 earlier reportsnormal: 12.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 23 Jun 2023Lobbying record

    GENEVANT SCIENCES, INC.: new lobbying registration (NOVEL STRATEGIES (FKA) PRISM GROUP) (dated 5 May 2023)

  19. 31 Mar 2023Lobbying record

    GENEVANT SCIENCES, INC.: new lobbying registration (S-3 GROUP) (dated 25 Feb 2023)

  20. 16 Mar 2023Filings record

    Director or officer change

  21. 21 Feb 2023Filings record

    Director or officer change

  22. 26 Nov 2022Short interest and volume change

    had 12.3M shares sold short in the 15 Nov 2022 report, 9.3× the same report last year.

    Same report last year: 1.3M; its normal report is 2.9M.

    See the evidence
    This period
    12.3M (the 15 Nov 2022 report)
    Normal report (median of 24 earlier)
    2.9M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +3.9
    Same report last year
    1.3M
    History used
    396 days
    2021-10-29: 1.3M2021-11-15: 1.3M2021-11-30: 1.1M2021-12-15: 1.3M2022-01-14: 2.6M2022-01-31: 2.7M2022-02-15: 2.9M2022-02-28: 2.9M2022-03-15: 2.8M2022-03-31: 2.9M2022-04-14: 2.4M2022-04-29: 2.3M2022-05-13: 2.3M2022-05-31: 3.6M2022-06-15: 6.0M2022-06-30: 6.5M2022-07-15: 8.2M2022-07-29: 8.6M2022-08-15: 9.4M2022-08-31: 10.0M2022-09-15: 10.4M2022-09-30: 11.3M2022-10-14: 11.7M2022-10-31: 12.3M2022-11-15: 12.3M
    the 15 Nov 2022 report24 earlier reportsnormal: 2.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 23 Nov 2022Filings record

    Director or officer change

  24. 15 Nov 2022Insiders record

    Oren Dan (ten percent owner) and 2 other(s) bought 4,000,000 shares of ROIV ($20.0M) (dated 14 Nov 2022)

  25. 10 Nov 2022Short interest and volume change

    had 12.3M shares sold short in the 31 Oct 2022 report, 9.5× the same report last year.

    Same report last year: 1.3M; its normal report is 2.9M.

    See the evidence
    This period
    12.3M (the 31 Oct 2022 report)
    Normal report (median of 24 earlier)
    2.9M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +3.9
    Same report last year
    1.3M
    History used
    381 days
    2021-10-15: 775K2021-10-29: 1.3M2021-11-15: 1.3M2021-11-30: 1.1M2021-12-15: 1.3M2022-01-14: 2.6M2022-01-31: 2.7M2022-02-15: 2.9M2022-02-28: 2.9M2022-03-15: 2.8M2022-03-31: 2.9M2022-04-14: 2.4M2022-04-29: 2.3M2022-05-13: 2.3M2022-05-31: 3.6M2022-06-15: 6.0M2022-06-30: 6.5M2022-07-15: 8.2M2022-07-29: 8.6M2022-08-15: 9.4M2022-08-31: 10.0M2022-09-15: 10.4M2022-09-30: 11.3M2022-10-14: 11.7M2022-10-31: 12.3M
    the 31 Oct 2022 report24 earlier reportsnormal: 2.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 21 Sep 2022Filings record

    Director or officer change

  27. 21 Sep 2022Filings record

    A major agreement ended

  28. 28 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 28 Jun 2022Filings record

    Director or officer change

  30. 27 Apr 2022Insiders record

    Dexcel Pharma Technologies Ltd. (ten percent owner) and 2 other(s) bought 40,285 shares of ROIV ($154,980) (dated 26 Apr 2022)

  31. 19 Apr 2022Lobbying record

    ROIVANT SCIENCES, INC.: lobbying engagement terminated (THE CONAFAY GROUP, LLC) (dated 1 Jan 2022)

  32. 31 Mar 2022Filings record

    Registered new securities for sale (S-1)

  33. 17 Feb 2022Filings record

    Registered new securities for sale (S-1) (dated 16 Feb 2022)

  34. 14 Feb 2022Institutional holdings record

    SB INVESTMENT ADVISERS (UK) LTD opened a $1.0B position (2021Q4 13F)

  35. 14 Feb 2022Institutional holdings record

    VIKING GLOBAL INVESTORS LP opened a $889.0M position (2021Q4 13F)

  36. 22 Dec 2021Filings record

    Registered new securities for sale (S-1)

  37. 29 Oct 2021Filings record

    Registered new securities for sale (S-1)

  38. 1 Oct 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 1 Oct 2021Filings record

    Director or officer change

  40. 19 Jul 2021Lobbying record

    ROIVANT SCIENCES, INC.: lobbying engagement terminated (BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ) (dated 17 Jun 2021)

Showing the newest 40 of 51 entries; narrow the window or the kind of data to see older ones.

Not listed: 239 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001635088
Ticker
ROIV
Domain
roivant.com
Employer name
Roivant Sciences, Inc. (1 unverified)
Hq location
|LONDON|SW1H (1 unverified)
Lobbying client
genevant sciences, peck madigan jones on behalf of roivant sciences, roivant sciences
Name
Company, Covant Therapeutics Operating, Inc, Genevant Sciences Corporation, Immunovant, Inc and 11 more
Wikipedia
Roivant Sciences
  • DOL H-1B labor condition applications and PERM certifications151 data points2 Dec 2019 to 11 May 2026
  • Federal lobbying disclosures (LDA)16 records, 98 data points6 Feb 2017 to 30 Sep 2026
  • SEC Form 13F institutional holdings2 records, 180 data points31 Dec 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)100 records21 Sep 2021 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)397 data points31 Mar 2020 to 3 Nov 2026
  • SEC Form 4 insider transactions158 records, 440 data points9 Mar 2022 to 18 Nov 2026
  • FINRA short interest (twice monthly)362 data points15 Oct 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2582 data points1 Oct 2021 to 20 Nov 2026
  • Wikipedia pageviews10 data points11 Nov 2026 to 20 Nov 2026